Founded in 2013, Glucovation has developed a continuous glucose monitoring system (CGM)
for the diabetic patient. CGM is the new technology replacing the old
technology of blood glucose (BG) meters. The BG meter market is $40B and
the CGM market is $1B with 30% CAGR.
Our CGM sensor is based on new sensing technology that is highly accurate, easy to use, and very low cost to manufacture, (high margins).
Glucovation has developed a novel CGM that addresses the deficiencies of the existing CGM systems. The main players currently in this market are chasing the triad of (1) high accuracy, (2) ease of use and (3) low cost to the patient, (which requires low manufacturing cost).
Our CGM system has been designed from the beginning to be highly accurate, easy to use and low cost to manufacture. We have (3) patents on our current technology and have obtained very good pre-clinical results. The market is very large, (greater than $1B), and growing fast, (CAGR ~ 30%). There are many companies, large and small, that are trying to enter this market. These potential strategic partners are insulin drug companies, insulin pump companies, blood glucose meter companies, medical device companies seeking entrance into this large and fast growing market, and other glucose sensing companies that desire a better sensor than their current products.
Our technology is developed and ready for confirmatory clinical trials.
Our strategy is to obtain ISO certification, conduct clinical trials and
file for regulatory approval. At the same time, we are cultivating
relationships with potential strategic partners. Obtaining the right
strategic partner(s), will allow us to leverage their existing
infrastructure and go to market quickly.
Glucovation achieves consistently solid in-vivo results with high accuracyOctober, 2018
Glucovation achieves consistently solid in-vitro resultsSeptember, 2018
Glucovation significantly improves sensor-build yieldsAugust, 2018
Glucovation develops Fused Membrane Technology™ (FMT) and files patentJuly, 2018
Glucovation halts clinical trials and refocuses on improving foundational sensor chemistry and sensor-build processDecember, 2017
Glucose sensor accuracy good but not good enoughNovember, 2017
Glucovation conducts a series of clinical trials in ChinaOctober, 2017
Glucovation obtains investment at a $20M valuationMarch, 2017
China Sun enters into Development AgreementMarch, 2016
China Sun invests in Glucovation at a $10M valuationSeptember, 2015
Glucovation files three patentsApril, 2014
Founders form Glucovation to develop novel and superior CGM technologyMay, 2013